EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arctic Bioscience AS's Enterprise Value is kr149.11 Mil.
Arctic Bioscience AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-45.40 Mil. Therefore, Arctic Bioscience AS's EV-to-FCF for today is -3.28.
The historical rank and industry rank for Arctic Bioscience AS's EV-to-FCF or its related term are showing as below:
OSL:ABS'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.58 Med: -1.94 Max: 0.36
Current: -3.25
During the past 8 years, the highest EV-to-FCF of Arctic Bioscience AS was 0.36. The lowest was -20.58. And the median was -1.94.
OSL:ABS's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs OSL:ABS: -3.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arctic Bioscience AS (OSL:ABS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arctic Bioscience AS's PE Ratio (TTM) for today is calculated as:
Arctic Bioscience AS's share price for today is kr3.19.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-1.529.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arctic Bioscience AS EV-to-FCF Related Terms
Arctic Bioscience AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arctic Bioscience AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's EV-to-FCF falls into.
Arctic Bioscience AS's current Enterprise Value is kr149.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-45.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS (OSL:ABS) has a EV-to-FCF of -3.28 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arctic Bioscience AS and its competitors. According to the industry distribution chart, Arctic Bioscience AS ranks #999999 out of 330 companies in the Biotechnology industry.
Is Arctic Bioscience AS's EV-to-FCF too high?
Arctic Bioscience AS's current EV-to-FCF is -3.28. Based on the distribution chart, Arctic Bioscience AS ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arctic Bioscience AS has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #999999 out of 330 companies for EV-to-FCF. This places Arctic Bioscience AS in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current EV-to-FCF is -3.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.61, compared to a current price of kr3.19 — trading 69.9% below its estimated fair value. The current EV-to-FCF is -3.28. Arctic Bioscience AS's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current EV-to-FCF is -3.28 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.19 is trading 69.9% below its estimated GF Value™ of kr10.61.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
EV-to-FCF: -3.28
GF Value™: kr10.61 vs. price of kr3.19 (69.9% below fair value)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
55GF Score
Get the complete analysis for OSL:ABS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
